Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 8, 2014, Pages 4922-4933

  Overby, Darryl R ^a   Bertrand, Jacques ^a   Tektas, Ozan Yüksel ^b   Boussommier Calleja, Alexandra ^a   Schicht, Martin ^b   Ross Ethier, C ^a,c   Woodward, David F ^d   Daniel Stamer, W ^e   Lütjen Drecoll, Elke ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d ALLERGAN INC   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Basement membrane; Steroid glaucoma; Trabecular meshwork

Indexed keywords

BASEMENT MEMBRANE; STEROID GLAUCOMA; TRABECULAR MESHWORK;

ACTINS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEA; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; OCULAR HYPERTENSION; PILOT PROJECTS;

EID: 84905714790     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14429     Document Type: Article

References (61)

1. Goldmann H. Cortisone glaucoma. Arch Ophthalmol. 1962; 68:621-626.
2. Bernstein HN, Schwartz B. Effects of long-term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol. 1962;68:742-753.
3. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. Arch Ophthalmol. 1963;70:482-491.
4. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. the demonstration of three levels of response. Invest Ophthalmol. 1965;4:187-197.
5. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965;4:198-205.
6. Becker B, Hahn KA. Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol. 1964;57: 543-551.
7. Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009;88:752-759.
8. Gerometta R, Podos SM, Candia OA, et al. Steroid-induced ocular hypertension in normal cattle. Arch Ophthalmol. 2004; 122:1492-1497.
9. Tektas O-Y, Hammer CM, Danias J, et al. Morphologic changes in the outflow pathways of bovine eyes treated with corticosteroids. Invest Ophthalmol Vis Sci. 2010;51:4060-4066.
10. Mao W, Tovar-Vidales T, Yorio T, Wordinger RJ, Clark AF. Perfusion-cultured bovine anterior segments as an ex vivo model for studying glucocorticoid-induced ocular hypertension and glaucoma. Invest Ophthalmol Vis Sci. 2011;52:8068- 8075.
11. Zhan GL, Miranda OC, Bito LZ. Steroid glaucoma: corticosteroid- induced ocular hypertension in cats. Exp Eye Res. 1992; 54:211-218.
12. Bhattacherjee P, Paterson CA, Spellman JM, Graff G, Yanni JM. Pharmacological validation of a feline model of steroidinduced ocular hypertension. Arch Ophthalmol. 1999;117: 361-364.
13. Ticho U, Lahav M, Berkowitz S, Yoffe P. Ocular changes in rabbits with corticosteroid-induced ocular hypertension. Br J Ophthalmol. 1979;63:646-650.
14. Candia OA, Gerometta R, Millar JC, Podos SM. Suppression of corticosteroid-induced ocular hypertension in sheep by anecortave. Arch Ophthalmol. 2010;128:338-343.
15. Gerometta R, Spiga M-G, Borràs T, Candia OA. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid- inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci. 2010;51:3042-3048.
16. Gerometta R, Podos SM, Danias J, Candia OA. Steroid-induced ocular hypertension in normal sheep. Invest Ophthalmol Vis Sci. 2008;50:669-673.
17. Miyara N, Shinzato M, Yamashiro Y, Iwamatsu A, Kariya K-I, Sawaguchi S. Proteomic analysis of rat retina in a steroidinduced ocular hypertension model: potential vulnerability to oxidative stress. Jpn J Ophthalmol. 2008;52:84-90.
18. Whitlock NA, McKnight B, Corcoran KN, Rodriguez LA, Rice DS. Increased intraocular pressure in mice treated with dexamethasone. Invest Ophthalmol Vis Sci. 2010;51:6496-6503.
19. Kumar S, Shah S, Tang HM, Smith M, Borràs T, Danias J. Tissue plasminogen activator in trabecular meshwork attenuates steroid induced outflow resistance in mice. PLoS One. 2013; 8:e72447.
20. Kumar S, Shah S, Deutsch ER, Tang HM, Danias J. Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes. Invest Ophthalmol Vis Sci. 2013;54:1280-1287.
21. Zode GS, Sharma AB, Lin X, et al. Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma. J Clin Invest. 2014;124:1956-1965.
22. Fingert JH, Clark AF, Craig JE, et al. Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroidinduced ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:145-152.
23. Johnson D, Gottanka J, Flügel C, Hoffmann F, Futa R, Lütjen- Drecoll E. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol. 1997;115:375-383.
24. Clark AF, Steely HT, Dickerson JE, et al. Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. Invest Ophthalmol Vis Sci. 2001;42:1769-1780.
25. Johnson DH, Knepper PA. Microscale analysis of the glycosaminoglycans of human trabecular meshwork: a study in perfusion cultured eyes. J Glaucoma. 1994;3:58-69.
26. Johnson DH, Bradley JM, Acott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci. 1990; 31:2568-2571.
27. Rohen JW, Linnèr E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroidglaucoma. Exp Eye Res. 1973;17:19-31.
28. Clark AF, Wilson K, De Kater AW, Allingham RR, McCartney MD. Dexamethasone-induced ocular hypertension in perfusion- cultured human eyes. Invest Ophthalmol Vis Sci. 1995; 36:478-489.
29. Smith RS, John SWM, Nishina PM, Sundberg JP. Systematic Evaluation of the Mouse Eye. Boca Raton, FL: CRC Press; 2001.
30. Overby DR, Bertrand J, Schicht M, Paulsen F, Stamer WD, Lütjen-Drecoll E. The structure of the trabecular meshwork, its connections to the ciliary muscle and the effect of pilocarpine on outflow facility in mice. Invest Ophthalmol Vis Sci. 2014; 55:3727-3736.
31. Savinova OV, Sugiyama F, Martin JE, et al. Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet. 2001;2:12.
32. Aihara M, Lindsey JD, Weinreb RN. Aqueous humor dynamics in mice. Invest Ophthalmol Vis Sci. 2003;44:5168-5173.
33. Lei Y, Overby DR, Boussommier-Calleja A, Stamer WD, Ethier CR. Outflow physiology of the mouse eye: pressure dependence and washout. Invest Ophthalmol Vis Sci. 2011;52: 1865-1871.
34. Boussommier-Calleja A, Bertrand J, Woodward DF, Ethier CR, Stamer WD, Overby DR. Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes. Invest Ophthalmol Vis Sci. 2012;53:5838-5845.
35. Li G, Farsiu S, Chiu SJ, et al. Pilocarpine-induced dilation of Schlemm's canal and prevention of lumen collapse at elevatedintraocular pressures in living mice visualized by OCT. Invest Ophthalmol Vis Sci. 2014;55:3737-3746.
36. Wang WH, Millar JC, Pang I-H, Wax MB, Clark AF. Noninvasive measurement of rodent intraocular pressure with a rebound tonometer. Invest Ophthalmol Vis Sci. 2005;46:4617-4621.
37. Johnson TV, Fan S, Toris CB. Rebound tonometry in conscious, conditioned mice avoids the acute and profound effects of anesthesia on intraocular pressure. J Ocul Pharmacol Ther. 2008;24:175-185.
38. Camras LJ, Sufficool KE, Camras CB, Fan S, Liu H, Toris CB. Duration of anesthesia affects intraocular pressure, but not outflow facility in mice. Curr Eye Res. 2010;35:819-827.
39. Boussommier-Calleja A, Overby DR. The influence of genetic background on conventional outflow facility in mice. Invest Ophthalmol Vis Sci. 2013;54:8251-8258.
40. Stamer WD, Lei Y, Boussommier-Calleja A, Overby DR, Ethier CR. eNOS, a pressure-dependent regulator of intraocular pressure. Invest Ophthalmol Vis Sci. 2011;52:9438-9444.
41. Overby D, Gong H, Qiu G, Freddo TF, Johnson M. The mechanism of increasing outflow facility during washout in the bovine eye. Invest Ophthalmol Vis Sci. 2002;43:3455-3464.
42. Ito S, Karnovsky MJ. Formaldehyde-glutaraldehyde fixatives containing trinitro compounds. J Cell Biol. 1968;39:168A-169A.
43. Dean RB, Dixon WJ. Simplified statistics for small numbers of observations. Anal Chem. 1951;23:636-638.
44. Lütjen-Drecoll E. Structural factors influencing outflow facility and its changeability under drugs. A study in Macaca arctoides. Invest Ophthalmol. 1973;12:280-294.
45. Mäepea O, Bill A. Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Exp Eye Res. 1992;54:879-883.
46. Rohen JW, Witmer R. Electron microscopic studies on the trabecular meshwork in glaucoma simplex. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1972;183:251-266.
47. Lütjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of "plaque material" in the inner and outer wall of Schlemm's canal in normal and glaucomatous eyes. Exp Eye Res. 1986;42:443-455.
48. Alvarado JA, Yun AJ, Murphy CG. Juxtacanalicular tissue in primary open angle glaucoma and in nonglaucomatous normals. Arch Ophthalmol. 1986;104:1517-1528.
49. Murphy CG, Johnson M, Alvarado JA. Juxtacanalicular tissue in pigmentary and primary open angle glaucoma. The hydrodynamic role of pigment and other constituents. Arch Ophthalmol. 1992;110:1779-1785.
50. Tektas O-Y, Lütjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res. 2009;88:769-775.
51. Lutjen-Drecoll E, Futa R, Rohen JW. Ultrahistochemical studies on tangential sections of the trabecular meshwork in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 1981;21: 563-573.
52. Johnson M. What controls aqueous humour outflow resistance? Exp Eye Res. 2006;82:545-557.
53. Overby DR, Stamer WD, Johnson M. The changing paradigm of outflow resistance generation: Towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res. 2009;88: 656-670.
54. Johnson M, Shapiro A, Ethier CR, Kamm RD. Modulation of outflow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci. 1992;33:1670-1675.
55. Dickerson JE, Steely HT, English-Wright SL, Clark AF. The effect of dexamethasone on integrin and laminin expression in cultured human trabecular meshwork cells. Exp Eye Res. 1998;66:731-738.
56. Snyder RW, Stamer WD, Kramer TR, Seftor RE. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res. 1993;57:461-468.
57. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993;34:3386-3395.
58. Flügel-Koch C, Ohlmann A, Fuchshofer R, Welge-Lüssen U, Tamm ER. Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro. Exp Eye Res. 2004; 79:649-663.
59. Underwood JL, Murphy CG, Chen J, et al. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol. 1999;277:C330-C342.
60. Fujimoto T, Inoue T, Kameda T, et al. Involvement of rhoA/rhoassociated kinase signal transduction pathway in dexamethasone- induced alterations in aqueous outflow. Invest Ophthalmol Vis Sci. 2012;53:7097-7108.
61. Lee YS, Tresguerres M, Hess K, et al. Regulation of anterior chamber drainage by bicarbonate-sensitive soluble adenylyl cyclase in the ciliary body. J Biol Chem. 2011;286:41353-41358.